Evolution and Bioinformatic Analysis of the Whole Genome Sequences of SARS-CoV-2
Variant Analysis of SARS-CoV-2 Genomes
Keywords:Covid-19, SARS-CoV-2, Virus Genome
Coronavirus Disease 2019 (COVID-19) disease, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus, has been spreading as a pandemic and health catastrophe. The increase in the rate of infection influenced the mutation rate to increase greatly. Mutations found in the spike protein site of SARS-CoV-2 may result in changes in the binding of the angiotensin-converting enzyme 2 (ACE2) receptor in the human respiratory mucosa, which is a significant step in infection, severity, and speed of the epidemic. Scientists are now recognizing and focusing on variant of concern (VOC) that are currently spreading and affecting: Alpha, Beta, Gamma, Delta, and Omicron. Therefore, to monitor and mitigate the spread of coronavirus-19, it is imperative to understand the structure, functions, and mutation of the virus. Bioinformatics is one tool used to determine strains in the genetic code data obtained by molecular biomolecular processes such as real-time polymerase chain reaction (RT-PCR), next generation sequencing (NGS), Mass Array and others. As the COVID-19 pandemic seems not to end soon, viruses continue to evolve, and this has given them a greater potential for infection and evasion of immunity, monitoring of viral genome is crucial.
Jamison DT, Wu KB. The East-West Divide in Response to COVID-19. Engineering (Beijing) 2021;7:936-47.
Calleja N, AbdAllah A, Abad N, Ahmed N, Albarracin D, Altieri E, et al. A Public Health Research Agenda for Managing Infodemics: Methods and Results of the First WHO Infodemiology Conference. JMIR Infodemiology 2021;1:e30979.
Kalia K, Saberwal G, Sharma G. The lag in SARS-CoV-2 genome submissions to GISAID. Nat Biotechnol 2021;39:1058- 60.
Van Noorden R. Scientists call for fully open sharing of coronavirus genome data. Nature 2021;590:195-6.
Paul P, France AM, Aoki Y, Batra D, Biggerstaff M, Dugan V, et al. Genomic Surveillance for SARS-CoV-2 Variants Circulating in the United States, December 2020-May 2021. MMWR Morb Mortal Wkly Rep 2021;70:846-50.
Wang H, Li X, Li T, Zhang S, Wang L, Wu X, et al. The genetic sequence, origin, and diagnosis of SARS-CoV-2. Eur J Clin Microbiol Infect Dis 2020;39:1629-35.
Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020;579:265-9.
who.int [homepage of the Internet]. Geneva: WHO; Weekly operational update on COVID-19 - 25 October 2021 [cited 2021 October 25]. Available from: https://www.who.int/emergencies/ diseases/novel-coronavirus-2019/situation-reports.
Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 2021;19:409-24.
Boopathi S, Poma AB, Kolandaivel P. Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment. J Biomol Struct Dyn 2021;39:3409-18.
Manzanares-Meza LD, Medina-Contreras O. SARS-CoV-2 and influenza: a comparative overview and treatment implications. Bol Med Hosp Infant Mex 2020;77:262-73.
Jogalekar MP, Veerabathini A, Gangadaran P. Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions. Exp Biol Med (Maywood) 2020;245:964-9.
Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin 2020;41:1141-9.
Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. Front Cell Infect Microbiol 2020;10:587269.
Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol 2020;5:562-9.
Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pohlmann S. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J Virol 2014;88:1293-307.
Rambaut A, Holmes EC, O’Toole A, Hill V, McCrone JT, Ruis C, et al. A dynamic nomenclature proposal for SARSCoV- 2 lineages to assist genomic epidemiology. Nat Microbiol 2020;5:1403-7.
Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data - from vision to reality. Euro Surveill 2017;22: 30494.
covariants.org [homepage of the Internet]. Bern: Emma Hodcroft; Variant:20I (Alpha, V1) [cited 27 October 2021]. Available from: https://covariants.org/variants/20I.Alpha.V1.
Starr TN, Greaney AJ, Hilton SK, Ellis D, Crawford KHD, Dingens AS, et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ace2 binding. Cell 2020;182:1295-310.
Firestone MJ, Lorentz AJ, Meyer S, Wang X, Como-Sabetti K, Vetter S, et al. First Identified Cases of SARS-CoV-2 Variant P.1 in the United States - Minnesota, January 2021. MMWR Morb Mortal Wkly Rep 2021;70:346-7.
Fujino T, Nomoto H, Kutsuna S, Ujiie M, Suzuki T, Sato R, et al. Novel SARS-CoV-2 Variant in Travelers from Brazil to Japan. Emerg Infect Dis 2021;27.
Sabino EC, Buss LF, Carvalho MPS, Prete CA, Jr, Crispim MAE, Fraiji NA, et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet 2021;397:452-5.
Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, et al. Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. medRxiv. 2021.
Motozono C, Toyoda M, Zahradnik J, Saito A, Nasser H, Tan TS, et al. SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. Cell Host Microbe 2021;29:1124-36.
Fisman DN, Tuite AR. Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada. CMAJ 2021;193:E1619–25.
Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, et al. Reduced neutralization of SARSCoV- 2 B.1.617 by vaccine and convalescent serum. Cell 2021;184:4220-36.
covariants.org [homepage of the Internet].Bern: Emma Hodcroft; Variant: 21A (Delta) [cited 2021 October]. Available from: https:// covariants.org/variants/21A.Delta.
Al-Tawfiq JA, Hoang VT, Le Bui N, Chu DT, Memish ZA. The Emergence of the Omicron (B.1.1.529) SARS-CoV-2 Variant: What is the Impact on the Continued Pandemic? J Epidemiol Glob Health 2022:1-4.
Callaway E. Heavily mutated Omicron variant puts scientists on alert. Nature 2021;600:21.
Chen J, Wang R, Gilby NB, Wei GW. Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance. J Chem Inf Model 2022;62:412-22.
Ai J, Zhang H, Zhang Y, Lin K, Zhang Y, Wu J, et al. Omicron variant showed lower neutralizing s-ensitivity than other SARSCoV- 2 variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect 2022;11:337-43.
How to Cite
Copyright (c) 2022 Author and Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.